3D C-Vit model improves tumor grading accuracy in 340 pediatric brain tumor cases.
New AI Tool Grades Pediatric Brain Tumors With 91% Accuracy
This retrospective cohort review evaluated a 3D C-Vit model against clinical and radiomics models in 340 pediatric brain tumor cases. The 3D…
A new AI tool grades pediatric brain tumors with 91% accuracy, helping doctors plan treatment faster and more reliably.
Adjuvant Imatinib Beyond 3 Years in High-Risk GIST: 5-Year Relapse-Free Survival Outcomes
Extending Imatinib beyond 3 years did not improve survival for high-risk GIST patients.
This retrospective cohort study evaluated adjuvant imatinib duration in 75 patients with high-risk GIST after radical surgery. Extending the…
A look at past data shows taking Imatinib longer than three years did not help high-risk GIST patients live longer or stay cancer-free.
Dried blood spot metabolomics shows promising breast cancer detection performance in 2,734 participants
Finger-Prick Test Spots Breast Cancer Early
This cohort study evaluated untargeted metabolomic profiling of dried blood spots for breast cancer detection among 2,734 participants (114 …
A new at-home style blood test can spot breast cancer with just a finger prick, offering hope for earlier detection without clinic visits.
Prognostic Nutritional Index and HALP Score Predict Lymph Node Metastasis in Breast Cancer
Low nutrition score predicts lymph node spread in breast cancer cases
This cohort study of 799 breast cancer patients found that 51.6% had lymph node metastasis (LNM). Lower HALP scores were significantly assoc…
A simple nutrition score predicts if breast cancer has spread to lymph nodes, helping doctors plan better care.
QDB method shows higher consistency than IHC for HER2 assessment in invasive breast cancer
New Test Finds Hidden Breast Cancer Targets
This observational cohort study compared a Quantitative Dot Blot (QDB) method to immunohistochemistry (IHC) for HER2 assessment in patients …
Some women told their breast cancer lacks a key target may actually benefit from powerful drugs — a new test can finally tell the difference…
CPX-351 first-line therapy shows 61% overall response in therapy-related AML or AML with myelodysplastic-related changes.
New AML Drug Shows Strong Response But Some Patients Face Higher Risk
This retrospective monocentric cohort study evaluated 60 consecutive patients treated with CPX-351 as first-line therapy for therapy-related…
A new leukemia drug helps most patients respond well, but those with high white blood cell counts or complex gene changes may face higher ri…
NDRG4 methylation in blood leukocytes associated with gastric cancer risk and prognosis in a case-control study.
Blood test reveals hidden risk factor for stomach cancer survival
This case-control study evaluated methylation of the NDRG4 gene in peripheral blood leukocytes among 310 gastric cancer patients and 300 con…
A simple blood test can now predict stomach cancer risk and how well chemotherapy will work for patients.
Qualitative review of tocilizumab use with bispecific antibodies in relapsed/refractory multiple myeloma
New drugs for myeloma need a safety net to work well
This qualitative interview review synthesizes perspectives from ten hematologists/oncologists regarding bispecific antibody (BsAb) use in re…
New powerful drugs treat myeloma better, but patients need a safety net to handle side effects and stay on track for a long time.
Software validation report shows single biomarkers often outperform panels for breast cancer diagnosis.
New Tool Finds the Tipping Point in Cancer Tests
This software validation report evaluates the TholdStormDX v0.0.1 tool across four diagnostic domains. Key findings indicate that for breast…
A new tool could help doctors decide exactly when a test result means cancer is likely — cutting down on missed cases and false alarms.
Narrative review suggests time-related biases may attenuate apparent vaccine survival benefits in cancer patients.
New math shows vaccine benefits in cancer care might be overstated
This narrative review and target trial emulation examines 3-year overall survival in cancer patients receiving COVID-19 vaccines versus thos…
A new look at the data reveals that timing errors made the vaccine look more powerful than it actually is for cancer patients.
Recurrence patterns in high-grade glioma after standard chemoradiotherapy: a retrospective review
Why tumors grow back inside the radiation beam, not just at the edges
This retrospective single-center review of 41 patients with high-grade glioma found that central recurrence was the most common pattern (36.…
New data shows brain tumors often return in the middle of the radiation zone, suggesting biology, not just targeting errors, drives failure.
Review highlights lack of comprehensive evaluation for atorvastatin anticancer mechanisms and therapeutic potential.
Review finds lack of research on atorvastatin's anticancer potential.
This narrative review discusses the potential anticancer mechanisms and therapeutic potential of atorvastatin. The authors note that a compr…
A review notes that a comprehensive evaluation of atorvastatin's anticancer mechanisms and potential is currently lacking.